IL1B and congenital rubella syndrome: In vitro experiments have shown that the monoclonal antibody Canakinumab targeting IL-1β also has therapeutic potential for CAR-T related CRS and neurotoxicity [29, 40], but there is currently no relevant clinical trial data available.